Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 2,10 M
EBIT 2016 -59,5 M
Net income 2016 -64,4 M
Debt 2016 -
Yield 2016 -
Sales 2017 0,35 M
EBIT 2017 -68,1 M
Net income 2017 -62,2 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 12,0x
Capi. / Sales2017 73,2x
Capitalization 25,3 M
More Financials
Company
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on developing and commercializing products to treat treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic... 
More about the company
Surperformance© ratings of ANTA PHAR
Trading Rating : Investor Rating :
More Ratings
Latest news on ANTA PHAR
01/17 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Anthera Pharmac..
01/13 Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violatio..
01/08 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Regulation FD Disclosu..
01/06 ANTHERA PHARMACEUTICALS INC : Regulation FD Disclosure (form 8-K)
2016 WEDNESDAY SECTOR LAGGARDS : Music & Electronics Stores, Biotechnology Stocks
2016 ANTHERA PHARMACEUTICALS : ANTH) Falls on Missing Endpoint
2016 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Other Events
2016 ANTHERA PHARMACEUTICALS INC (NASDAQ : ANTH) Looks Good For A Recovery
2016 ANTHERA PHARMACEUTICALS : Announces the Phase 3 SOLUTION Study with Sollpura in ..
2016 ANTHERA PHARMACEUTICALS INC : Other Events (form 8-K)
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 5
Average target price 2,85 $
Spread / Average Target 373%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John Craig Thompson President, Chief Executive Officer & Director
Paul F. Truex Executive Chairman
May Liu CAO, Senior VP-Finance & Administration
Charles V. Olson Chief Technology Officer
William R. Shanahan Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ANTA PHAR25
AMGEN, INC.5.79%115 062
GILEAD SCIENCES, INC.-0.84%93 553
CELGENE CORPORATION-2.67%87 334
REGENERON PHARMACEUTIC..-1.23%38 239
ACTELION LTD1.18%23 977
More Results